(Reuters) -Pfizer ( PFE ) is closing in on a potential $7.3 billion takeover of anti-obesity drug developer Metsera ( MTSR ), the Financial Times reported on Sunday, citing unidentified sources.

Pfizer ( PFE ) will pay Metsera ( MTSR ) $47.50 in cash per share and a further $22.50 if certain performance milestones are met, the newspaper said, adding that the announcement could come as early as Monday.

Reuters could not immediately confirm the report.

Metsera ( MTSR ) and Pfizer ( PFE ) did not immediately respond to a Reuters request for comment outside regular business hours.